B. Riley Predicts Lower Earnings for Foghorn Therapeutics

Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - B. Riley lowered their Q2 2025 earnings per share (EPS) estimates for Foghorn Therapeutics in a research report issued on Wednesday, May 14th. B. Riley analyst K. Patel now anticipates that the company will post earnings of ($0.36) per share for the quarter, down from their previous forecast of ($0.32). B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for Foghorn Therapeutics' current full-year earnings is ($1.55) per share. B. Riley also issued estimates for Foghorn Therapeutics' Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.49) EPS, FY2026 earnings at ($1.44) EPS and FY2027 earnings at ($1.89) EPS.

Other equities research analysts have also issued reports about the stock. Citizens Jmp began coverage on shares of Foghorn Therapeutics in a report on Wednesday, April 23rd. They issued a "mkt outperform" rating and a $9.00 price objective for the company. JMP Securities reissued a "market outperform" rating and issued a $9.00 price target on shares of Foghorn Therapeutics in a research note on Thursday, May 15th. Citigroup began coverage on Foghorn Therapeutics in a research note on Wednesday, April 23rd. They issued an "outperform" rating for the company. Finally, HC Wainwright raised Foghorn Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $12.13.

Foghorn Therapeutics Stock Performance

Shares of FHTX remained flat at $4.14 during mid-day trading on Monday. 70,400 shares of the stock were exchanged, compared to its average volume of 141,045. The firm has a market capitalization of $230.77 million, a PE ratio of -2.16 and a beta of 3.13. Foghorn Therapeutics has a 1 year low of $2.94 and a 1 year high of $10.25. The stock's 50 day moving average price is $3.94 and its two-hundred day moving average price is $5.04.

Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.30). The firm had revenue of $5.95 million during the quarter, compared to the consensus estimate of $4.96 million.

Institutional Investors Weigh In On Foghorn Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hsbc Holdings PLC raised its stake in shares of Foghorn Therapeutics by 12.4% during the fourth quarter. Hsbc Holdings PLC now owns 18,728 shares of the company's stock valued at $88,000 after acquiring an additional 2,061 shares during the last quarter. Sherbrooke Park Advisers LLC raised its position in Foghorn Therapeutics by 22.2% during the 4th quarter. Sherbrooke Park Advisers LLC now owns 15,617 shares of the company's stock valued at $74,000 after purchasing an additional 2,841 shares during the last quarter. Northern Trust Corp raised its position in Foghorn Therapeutics by 1.1% during the 4th quarter. Northern Trust Corp now owns 253,671 shares of the company's stock valued at $1,197,000 after purchasing an additional 2,873 shares during the last quarter. Rhumbline Advisers raised its position in Foghorn Therapeutics by 9.1% during the 4th quarter. Rhumbline Advisers now owns 36,384 shares of the company's stock valued at $172,000 after purchasing an additional 3,049 shares during the last quarter. Finally, Wells Fargo & Company MN raised its position in Foghorn Therapeutics by 33.3% during the 4th quarter. Wells Fargo & Company MN now owns 15,841 shares of the company's stock valued at $75,000 after purchasing an additional 3,958 shares during the last quarter. 61.55% of the stock is currently owned by institutional investors.

About Foghorn Therapeutics

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.